Overview

This trial is active, not recruiting.

Condition healthy
Treatment hantavax injection
Phase phase 3
Sponsor Green Cross Corporation
Start date November 2015
End date August 2017
Trial size 317 participants
Trial identifier NCT02553837, GC3101B_P3

Summary

This study was aimed to evaluate the Immunogenicity and Safety response by vaccinating Hantavax in Healthy Adult.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose prevention
Arm
(Experimental)
Drug: Hantavax injectionSchedule: The basic vaccination(0, 1, 2months) and The boost vaccination(13months)
hantavax injection
A single 0.5mL dose intramuscular or subcutaneous injection

Primary Outcomes

Measure
The Antibody Seroconversion rates by neutralizing antibody test at 28 days after the 3rd vaccination(2month)
time frame: 3 months

Secondary Outcomes

Measure
The Antibody Seroconversion Rates by fluorescent antibody test at 28 days after the 3rd vaccination(2month)
time frame: 3 months
The Antibody Seroconversion Rates by neutralizing antibody test and fluorescent antibody test at 28 days after the 2nd vaccination(1month)
time frame: 2 months
The Antibody Seroconversion Rates by neutralizing antibody test and fluorescent antibody test at 28 days after the 4th vaccination(13month)
time frame: 14 months
The Antibody Seroconversion Rates by neutralizing antibody test and fluorescent antibody test at 2 , 4, 12, 24, 36, 48, 60months after the 4th vaccination(13month)
time frame: 15, 17, 25, 37, 49, 61, 73months
Geometric Mean Titer(GMT) at 28 days after the 2nd vaccination(1month)
time frame: 2 months
Geometric Mean Titer(GMT) at 28 days after the 3rd vaccination(2month)
time frame: 3 months
Geometric Mean Titer(GMT) at 28 days after the 4th vaccination(13month)
time frame: 14 months
Geometric Mean Titer(GMT) at 2, 4, 12, 24, 36, 48, 60 after the 4th vaccination(13month)
time frame: 15, 17, 25, 37, 49, 61, 73months
The Antibodies retention duration per the neutralizing antibody test
time frame: 5 years
The Antibodies retention duration per the fluorescent antibody test
time frame: 5 years

Eligibility Criteria

Male or female participants at least 19 years old.

Inclusion Criteria: - Healthy adults ≥ 19years old. - Subjects who have not the hantavax vaccination history at the time of screening. Exclusion Criteria: - Subject who did not passed by 2 weeks after recovering the acute disease. - immunologic dysfunction subjects. - Subjects previously treated with anti-coagulant therapy or hemophiliac patients. - Subjects with severe chronic diseases. - Subjects who had an acute before vaccinating IP. - Subjects who had received another vaccination during the 28 days before vaccinating IP or who were scheduled for another vaccination during the study. - Subjects who were receiving immunosuppressant or immune modifying drug - Subjects who had been administered immunoglobulins or blood-derived products 3 months before vaccinating IP or who were scheduled for the administration during the study. - Subjects of childbearing potential at the time of screening and were scheduled to pregnancy for the study. A female subject who was pregnant or who was breast-feeding

Additional Information

Official title Study to Evaluate the Immunogenicity and Safety of Hantavax in Healthy Adult
Principal investigator Woo Joo Kim, MD
Description This clinical trial was designed as a multicenter, non-comparative, open-label clinical trial. This trial was conducted, written informed consent form by voluntary agreement, the subjects who have not had the hantavax vaccination history at the time of screening. Investigator product was administrated 0, 1, 2, 13 months. For antibody test, Sampling was conducted pre-dose(T0), 28 days after the 2nd vaccination(before the 3rd vaccination, T1), 28 days after the 3rd vaccination(T2) and 11 months after the 3rd vaccination(before booster vaccination, T3), 28 days after the booster vaccination(T4), 2 months after the booster vaccination(T5) and 4 months after the booster vaccination(T6). Also, after the completion of booster vaccination for antibody retention duration observed for subjects with antibody to conduct a five-year follow-up survey was conducted, and the antibody test every year. In conclusion, sampling was conducted 12 months(T7), 24 months(T8), 36months(T9), 48 months(T10), 60 months(T11) after the booster vaccination. However, follow-up survey was terminated when the antibody titer was determined as a negative by neutralizing antibody test and fluorescent antibody technique.
Trial information was received from ClinicalTrials.gov and was last updated in January 2016.
Information provided to ClinicalTrials.gov by Green Cross Corporation.